Response to Letter Regarding Article “Effects of the Selective Estrogen Receptor Modulator Raloxifene on Coronary Outcomes in the Raloxifene Use for the Heart Trial: Results of Subgroup Analyses by Age and Other Factors”

Peter Collins,Mary Jane Geiger,Sherie Dowsett,Lori Mosca,Deborah Grady,Marcel Kornitzer,Nanette K Wenger,Elizabeth Barrett-Connor,Messan G Amewou-Atisso,Mark B Effron

doi:10.1161/circulationaha.109.876920

Response to Letter Regarding Article “Effects of the Selective Estrogen Receptor Modulator Raloxifene on Coronary Outcomes in the Raloxifene Use for the Heart Trial: Results of Subgroup Analyses by Age and Other Factors”

Peter Collins, Mary Jane Geiger + Show 8 more

Open Access

https://doi.org/10.1161/circulationaha.109.876920

Copy DOI

Journal: Circulation	Publication Date: Oct 26, 2009
Citations: 2

Affiliation: Imperial College London, Eli Lilly (United States), Columbia University, University of California, San Francisco, Emory University, University of California, San Diego

#Raloxifene Use For The Heart #Selective Estrogen Receptor Modulator Raloxifene + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

We thank Dr Choi and colleagues for their correspondence and intriguing hypothesis. Unfortunately, we do not have the additional data with which to confidently test the hypothesis stated. We do not have robust osteoporosis data in the Raloxifene Use for the Heart (RUTH) study; we did not systematically measure bone mineral density. In addition, few women (<10% before data lock) reported osteoporosis as a secondary condition. Approximately 15% reported postbaseline use of bone-active agents. For reported …

Full Text